NanoViricides
NNVC
$1.12
Share price
1.82%
Change (1 day)
-15.79%
Change (1 year)
Categories
NanoViricides (NNVC) - Total liabilities
Total liabilities on the balance sheet as of December 2023 : $0.95 M
According to NanoViricides's latest financial reports the company's total liabilities are $0.95 M. A company’s total liabilities is the sum of all current and non-current debts and obligations.
NanoViricides - Total liabilities on balance sheet (from 2006 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2023-06-30 | $2.03 M | 392.75% |
| 2022-06-30 | $0.41 M | 17.57% |
| 2021-06-30 | $0.35 M | -83.72% |
| 2020-06-30 | $2.15 M | -24.29% |
| 2019-06-30 | $2.84 M | 222.94% |
| 2018-06-30 | $0.88 M | -86.8% |
| 2017-06-30 | $6.68 M | -50.82% |
| 2016-06-30 | $13.58 M | 9.55% |
| 2015-06-30 | $12.4 M | -39.48% |
| 2014-06-30 | $20.49 M | 144% |
| 2013-06-30 | $8.39 M | 371.89% |
| 2012-06-30 | $1.77 M | 203.08% |
| 2011-06-30 | $0.58 M | -76.26% |
| 2010-06-30 | $2.47 M | 379.65% |
| 2009-06-30 | $0.51 M | -49.66% |
| 2008-06-30 | $1.02 M | 20.55% |
| 2007-06-30 | $0.84 M | -43% |
| 2006-06-30 | $1.49 M | 2159.13% |
| 2005-06-30 | $0.06 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Gilead Sciences GILD | $39.37 B | 4,140,061.54% | 🇺🇸 USA |
 Merck MRK | $69.04 B | 7,259,061.75% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $82.48 B | 8,672,516.43% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $58.82 B | 6,185,044.37% | 🇬🇧 UK |
 Novavax NVAX | $2.51 B | 264,276.90% | 🇺🇸 USA |
 BioCryst Pharmaceuticals
BCRX | $0.97 B | 102,151.56% | 🇺🇸 USA |